Immunosuppressive Agents on the Horizon

Journal of Pharmacy Practice

Volumn 16, Issue 6, 2003, Pages 434-441

  McDevitt, Lisa M ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF UTAH HOSPITAL   (United States)

Author keywords

Immunosuppression; Novel agents; Transplantation

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; 32 O [1 (2 HYDROXYETHYL) 5 INDOLYL]ASCOMYCIN; ACSA; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; FINGOLIMOD; FK MR; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE INHIBITOR; ISATX 247; L 732 531; LEFLUNOMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; OKT4A; ORTHOCLONE OKT4A; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ANEMIA; BRADYCARDIA; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; MUCOCUTANEOUS REACTION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VOMITING;

EID: 1642536398     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003259384     Document Type: Review

References (41)

1. FDC Reports, Inc. NDA pipeline. Retrieved June 18, 2003, from http://www.ndapipeline.com.
2. Keenan RJ, Iacono A, Dauber JH, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg. 1997;113(2):335-340.
3. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med. 1996;153(4 pt 1):1451-1455.
4. Abel MD, Aspeslet LJ, Freitag DG, et al. ISATX247: a novel calcineurin inhibitor [abstract 36]. J Heart Lung Transplant. 2001;20(2):161.
5. Peterson LB, Cryan JG, Rosa R, et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation. 1998;65(1):10-18.
6. Dumont FJ, Koprak S, Staruch MJ, et al. A tacrolimus-related immunosuppressant with reduced toxicity. Transplantation. 1998;65(1):18-26.
7. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc. 2001;33:3241-3244.
8. Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al. Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant recipients. Pediatr Transpl. 2002;6(2):147-152.
9. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transplantation. 2001;7(6):473-484.
10. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69(1):48-56.
11. Kovarik JM, Kaplan B, Tedesco-Silva H, et al. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation. 2002;73(6):920-925.
12. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42(1):95-99.
13. Vitko S, Margreiter R, Weimar W, et al. International, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral® and steroids [abstract 1337]. Am J Transplant. 2001;1(suppl 1):474.
14. Kaplan B, Tedesco-Silva H, Mendez R, et al. North/South American, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral® and corticosteroids [abstract 1339]. Am J Transplant. 2001;1(suppl 1):475.
15. Oppenheimer F, Oyen O, Viljoen H, et al. 36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients [abstract 1201]. Am J Transplantation. 2003;3(suppl 5):459.
16. Curtis J, Nashan B, Ponticelli C, et al. One year results of a multicenter, open-label trial on safety and efficacy of Certican™ (RAD) used in combination with Simulect, corticosteroids, and full or reduced dose Neoral® in renal transplantation [abstract 1335]. Am J Transplant. 2001;1(suppl 1):474.
17. Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73(3):358-366.
18. Leflunomide (Arava™) [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals; 2002.
19. Hardinger KL, Wang CD, Schnitzler MA, et al. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant. 2002;2(9):867.
20. Schorlemmer HU. Development of a novel drug for transplantation: current results and future perspectives. Transplant Proc. 2001;33:2425-2429.
21. Public Citizen's Health Research Group. Letter to FDA, March 28, 2002. Retrieved from http://www.citizen.org/documents/1614.pdf.
22. Jin MB, Nakayama M, Ogata T, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery. 2002;132:72.
23. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-349.
24. Kahan B, Chodoff L, Leichtman A, et al. Safety and pharmacodynamics of multiple doses of FTY720 in stable renal transplant recipients [abstract 654]. Am J Transplant. 2001;1(suppl 1):300.
25. Kahan B. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Therap Drug Mon. 2002;24:47-52.
26. Tedesco H, Kahan BD, Mourad G, et al. FTY720 combined with Neoral® and corticosteroids is effective and safe in prevention of acute rejection in renal allograft recipients-interim data [abstract 429]. Am J Transplant. 2001;1(suppl 1):243.
27. Ferguson RM, Mulgaonkar S, Tedesco H, et al. High efficacy of FTY720 with reduced cyclosporine dose in preventing rejection in renal transplantation: 12-month preliminary results [abstract 624]. Am J Transplant. 2003;3(suppl 5):311.
28. Vincenti F. New monoclonal antibodies in renal trans-plantation. Minerva Urol Nefrol. 2003;55(1):57-66.
29. Vincenti F. What's in the pipeline? New immunosuppressive drugs in transplantation. Am J Transplant. 2002;2:898-903.
30. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001;1(6):1059-1065.
31. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation. 1999;68(10):1613-1616.
32. Tzakis AG, Kato T, Nishida S, et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation. 2003;75(8):1227-1231.
33. Reams BD, Davis RD, Curl J, et al. Treatment of refractory acute rejection in a lung transplant recipient with Campath 1H. Transplantation. 2002;74(6):903-904.
34. Garrett HE Jr, Groshart K, Duvall-Seaman D, et al. Treatment of humoral rejection with rituximab. Ann Thorac Surg. 2002;74(4):1240-1242.
35. Aranda JM Jr, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73(6):907-910.
36. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation. 2002;74(9):1207-1210.
37. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood. 1990;75:1037-1050.
38. Vincenti F, Mendez R, Rajagopalan PR, et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation [abstract 562]. Am J Transplant. 2001;1(suppl 1):276.
39. Norman DJ, Vicenti F, de Mattos AM, et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation. 2000;70(12):1707-1712.
40. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation. 1999;68(5):608-616.
41. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Transplantation. 1997;63(9):1243-1251.